Compare Citius Pharmaceuticals Inc (CTXR) vs Invesco DB Agriculture Fund (DBA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Invesco DB Agriculture Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Invesco DB Agriculture Fund trades at $28.53 (market cap $1.32B). The key difference: Invesco DB Agriculture Fund is far larger — about 96.9× Citius Pharmaceuticals Inc's market cap, and Invesco DB Agriculture Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Invesco DB Agriculture Fund for 24 Days on average.
| CTXR | DBA | |
|---|---|---|
Market Cap | $13.62M | $1.32B |
Volume | 132,438 | 771,657 |
Sector | Health | — |
52-Week High | $1.82 | $29.49 |
52-Week Low | $0.48 | $25.44 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong year-to-date performance with 12.4% returns matching the S&P 500. The technical outlook remains bullish with moving averages signaling strength and ADX indicators confirming trend momentum. Recent news highlights agricultural ETF outperformance driven by weather risks, geopolitical tensions, and strong global demand for commodities.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and climate factors, though the 0.85% expense ratio and commodity volatility present risks. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish technical consolidation near all-time highs since 2020.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →
